Nanhua Bio Medicine Stock Fundamentals
| 000504 Stock | 10.07 0.09 0.89% |
Nanhua Bio Medicine fundamentals help investors to digest information that contributes to Nanhua Bio's financial success or failures. It also enables traders to predict the movement of Nanhua Stock. The fundamental analysis module provides a way to measure Nanhua Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nanhua Bio stock.
At present, Nanhua Bio's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Cost Of Revenue is expected to grow to about 69.4 M, whereas Selling General Administrative is forecasted to decline to about 43 M. Nanhua | Select Account or Indicator |
Nanhua Bio Medicine Company Current Valuation Analysis
Nanhua Bio's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Nanhua Bio Current Valuation | 3.03 B |
Most of Nanhua Bio's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nanhua Bio Medicine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Nanhua Bio Medicine has a Current Valuation of 3.03 B. This is 89.44% lower than that of the Media sector and significantly higher than that of the Communication Services industry. The current valuation for all China stocks is 81.76% higher than that of the company.
Nanhua Bio Medicine Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nanhua Bio's current stock value. Our valuation model uses many indicators to compare Nanhua Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nanhua Bio competition to find correlations between indicators driving Nanhua Bio's intrinsic value. More Info.Nanhua Bio Medicine is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nanhua Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nanhua Bio's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Nanhua Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nanhua Bio's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nanhua Bio could also be used in its relative valuation, which is a method of valuing Nanhua Bio by comparing valuation metrics of similar companies.Nanhua Bio is currently under evaluation in current valuation category among its peers.
Nanhua Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.0455 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 3.03 B | ||||
| Shares Outstanding | 330.02 M | ||||
| Shares Owned By Insiders | 13.01 % | ||||
| Shares Owned By Institutions | 40.52 % | ||||
| Price To Book | 13.37 X | ||||
| Price To Sales | 26.70 X | ||||
| Revenue | 136.79 M | ||||
| Gross Profit | 127.36 M | ||||
| EBITDA | (38.19 M) | ||||
| Net Income | (28.17 M) | ||||
| Total Debt | 28.12 M | ||||
| Book Value Per Share | 0.75 X | ||||
| Cash Flow From Operations | 36.28 M | ||||
| Earnings Per Share | (0.12) X | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 3.32 B | ||||
| Total Asset | 771.38 M | ||||
| Retained Earnings | (531.1 M) | ||||
| Working Capital | 202.45 M | ||||
| Net Asset | 771.38 M |
About Nanhua Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nanhua Bio Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nanhua Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nanhua Bio Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 136.8 M | 117.7 M | |
| Cost Of Revenue | 43.7 M | 69.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Nanhua Stock
Nanhua Bio financial ratios help investors to determine whether Nanhua Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nanhua with respect to the benefits of owning Nanhua Bio security.